ArticleCureus2025
Lessons From the Edge of Reactivation: Managing Herpes Simplex Virus Encephalitis Years After Initial Infection in High-Risk Neurosurgical Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex encephalitis (HSE) is a severe central nervous system infection with significant morbidity and mortality. While rare, reactivation of HSE following neurosurgical procedures is increasingly reported, particularly in patients with a previously clinically significant HSE, which is the most critical risk factor for reactivation. This case highlights the challenges of managing HSE reactivation risk in pediatric patients with a history of HSE, who are considered high risk due to their susceptibility to viral reactivation. As demonstrated in a nine-year-old girl with intractable epilepsy who underwent corpus callosotomy, postoperative day seven was marked by fever, altered consciousness, and seizures. Delayed antiviral therapy led to severe neurological sequelae. Identified risk factors included perioperative steroid use and surgical stress, with the history of HSE standing out as the predominant risk factor. This case underscores the importance of defining high-risk groups, specifically patients with a prior history of HSE, and proactively managing their care, including consideration of prophylactic antiviral therapy. Early recognition, timely intervention, and comprehensive perioperative strategies are essential to mitigating the risk of severe outcomes in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.